Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?

Hologic (HOLX) reported a non-GAAP gross margin of 61.1% for fiscal Q2 2025, a 40 bps increase year-over-year, driven by diagnostics and recent acquisitions, while maintaining a 30% operating margin. Despite a slight revenue dip and increased operating expenses due to acquisitions, disciplined cost management helped offset losses; however, the company is taking a cautious stance for the full year due to tariff impacts expected to add $20-$25 million to quarterly costs and a reduced China revenue forecast by $20 million to $50 million. Hologic anticipates diagnostics and surgical segments to drive growth, supporting gross margins in the low 60s and operating margins in the low 30s for the full year, even with tariff headwinds.

Analysis

Hologic demonstrated operational resilience in its fiscal second quarter of 2025, achieving a 40 basis point year-over-year increase in non-GAAP gross margin to 61.1%, primarily driven by robust diagnostic sales and contributions from recent high-margin acquisitions, Endomagnetics and Gynesonics. Despite these acquisitions elevating operating expenses by 1.7%, underlying cost discipline was evident with a 4.6% year-over-year reduction in expenses excluding these additions, even as revenues experienced a slight 0.5% dip at constant currency. The company maintained a strong 30% operating margin, an improvement of 60 basis points sequentially and a leading figure compared to peers like GE Healthcare (15% adjusted EBIT margin) and Bio-Rad (10.8% non-GAAP operating margin). However, Hologic has adopted a cautious full-year outlook, citing anticipated tariff impacts of $20 million to $25 million on quarterly cost of goods sold, a $20 million reduction in its China revenue forecast to $50 million, and the removal of its $50 million HIV testing business following the cessation of USAID funding. Growth for the year is expected to be spearheaded by the Diagnostics segment (mid-single-digit growth) and the Surgical segment (high-single-digit growth), supported by new products like the Fluent Pro Fluid Management System and an accelerated recovery in Skeletal product supply. These factors are projected to sustain gross margins in the low 60s and operating margins in the low 30s for the full year, despite intensifying tariff pressures. Hologic's shares have declined 10.4% over the past six months, slightly outperforming the industry's 13.8% fall, yet the stock trades at a forward price-to-sales ratio of 3.42X, notably above the sector average, and currently carries a Zacks Rank #4 (Sell) alongside a negative per-ticker sentiment score of -0.3.

Key Decisions for Investors

• Investors should carefully evaluate Hologic's ability to sustain its strong gross and operating margins amid significant headwinds from tariffs, reduced China revenue projections, and the discontinuation of USAID-funded business, which underpin its cautious full-year outlook.
• Consider the current valuation, with a price-to-sales ratio above the sector, in the context of identified operational risks, the stock's recent performance, the negative sentiment score of -0.3, and the Zacks Rank #4 (Sell) recommendation.
• Closely monitor the execution of growth strategies within the Diagnostics and Surgical segments, particularly the uptake of new products and international sales momentum, as these are critical for offsetting the aforementioned financial pressures and achieving guided performance targets.